Related Experiment Video
Updated: Jul 11, 2026
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Preconditioning and postconditioning: new strategies for cardioprotection
1The Hatter Cardiovascular Institute, University College, London, London, UK.
Diabetes, Obesity & Metabolism
|September 11, 2007
Summary
New cardioprotection strategies are needed for coronary heart disease (CHD). Ischaemic postconditioning (IPost) offers a promising approach by intervening during reperfusion, unlike preconditioning, to protect the heart.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Coronary heart disease (CHD) poses significant morbidity and mortality risks, especially in patients with diabetes or metabolic syndrome.
- Current therapies are insufficient, necessitating novel cardioprotective strategies.
- Ischaemic preconditioning (IPC) has limited clinical utility due to its requirement for intervention before an ischaemic event.
Purpose of the Study:
- To explore ischaemic postconditioning (IPost) as a cardioprotective strategy for acute myocardial infarction (AMI).
- To investigate the shared signalling pathways between IPC and IPost.
- To highlight the potential of pharmacological agents targeting these pathways for improved cardioprotection during reperfusion.
Main Methods:
- Review of emerging studies on IPC and IPost.
- Analysis of signalling transduction pathways involved in myocardial reperfusion protection.
- Discussion of pharmacological interventions for AMI.
Main Results:
- IPC-induced protection is partly mediated by reperfusion signalling pathways.
- IPost allows intervention during reperfusion, making it applicable to AMI.
- IPC and IPost appear to recruit common cardioprotective signalling pathways.
Conclusions:
- IPost represents a viable cardioprotective strategy for AMI.
- Targeting common reperfusion signalling pathways offers a novel therapeutic avenue.
- Pharmacological manipulation of these pathways can enhance current reperfusion strategies for AMI.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.